

Morten Lamberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7098274/publications.pdf>

Version: 2024-02-01

79
papers

4,642
citations

117625

34
h-index

98798

67
g-index

79
all docs

79
docs citations

79
times ranked

6612
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long-term beta-blocker effect on cardiovascular prognosis. <i>European Heart Journal</i> , 2022, 43, 836-838.	2.2	2
2	Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. <i>Heart</i> , 2022, 108, 626-632.	2.9	10
3	Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. <i>American Journal of Medicine</i> , 2022, 135, 595-602.e5.	1.5	8
4	Protocol for detecting unrecognized sleep apnea in patients with atrial fibrillation by a home-monitoring device: the DAN-APNO study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 6.	1.7	3
5	Outcomes of prolonged dual anti-platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A nationwide registry-based study. <i>American Heart Journal</i> , 2022, 245, 81-89.	2.7	3
6	The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes. <i>Clinical Research in Cardiology</i> , 2022, 111, 460-468.	3.3	0
7	Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease. <i>Annals of Internal Medicine</i> , 2022, 175, 774-782.	3.9	7
8	Incidence of acute coronary syndrome during national lock-down: Insights from nationwide data during the Coronavirus disease 2019 (COVID-19) pandemic. <i>American Heart Journal</i> , 2021, 232, 146-153.	2.7	13
9	Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study. <i>Heart Rhythm O2</i> , 2021, 2, 304-308.	1.7	10
10	Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study. <i>European Heart Journal</i> , 2021, 42, 2899-2908.	2.2	7
11	Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study. <i>Journal of Ultrasound</i> , 2021, , 1.	1.3	1
12	Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. <i>European Heart Journal</i> , 2021, 42, 907-914.	2.2	37
13	Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 292-300.	3.0	20
14	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020, 142, 2080-2082.	1.6	168
15	Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. <i>ESC Heart Failure</i> , 2020, 7, 4189-4197.	3.1	77
16	Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. <i>Thorax</i> , 2020, 75, 928-933.	5.6	6
17	Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark. <i>Circulation: Heart Failure</i> , 2020, 13, e007274.	3.9	90
18	New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. <i>European Heart Journal</i> , 2020, 41, 3072-3079.	2.2	93

#	ARTICLE	IF	CITATIONS
19	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2019, 18, 79.	6.8	26
20	Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12% year follow up study. <i>BMC Cancer</i> , 2019, 19, 1105.	2.6	68
21	Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 6, 23-31.	4.0	10
22	The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Europace</i> , 2019, 21, 572-580.	1.7	9
23	Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy: A nationwide study in patients with osteoarthritis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 629-641.	2.5	27
24	CHA ₂ DS ₂ -VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 651-658.	1.8	72
25	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2018, 39, 1698-1705a.	2.2	28
26	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. <i>Europace</i> , 2018, 20, e78-e86.	1.7	22
27	Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. <i>Heart</i> , 2018, 104, 912-920.	2.9	16
28	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1790-1800.	2.8	41
29	Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 17-26.	2.8	47
30	Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	30
31	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 91.	1.7	21
32	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	109
33	Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2901-2909.	2.8	19
34	Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study. <i>Europace</i> , 2017, 19, 1007-1014.	1.7	30
35	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. <i>Scientific Reports</i> , 2017, 7, 3347.	3.3	36
36	Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 511-521.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. <i>Europace</i> , 2016, 18, 492-500.	1.7	11
38	Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.	1.6	50
39	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2016, 38, ehv496.	2.2	74
40	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , 2016, 6, 31477.	3.3	80
41	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 108-118.	3.0	35
42	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 1015-1023.	2.2	109
43	Atrial fibrillation and risk of stroke: a nationwide cohort study. <i>Europace</i> , 2016, 18, 1689-1697.	1.7	45
44	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2015, 17, 828-836.	7.1	34
45	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2015, 17, 1215-1222.	1.7	28
46	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 516-518.	2.8	1
47	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. <i>Europace</i> , 2015, 17, 187-193.	1.7	152
48	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 115, 1185-1193.	1.6	65
49	Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 805.	7.4	115
50	Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. <i>BMJ, The</i> , 2015, 351, h5096.	6.0	22
51	Relation of Nonsteroidal Anti-inflammatory Drugs to Serious Bleeding and Thromboembolism Risk in Patients With Atrial Fibrillation Receiving Antithrombotic Therapy. <i>Annals of Internal Medicine</i> , 2014, 161, 690.	3.9	81
52	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. <i>Europace</i> , 2014, 16, 477-484.	1.7	107
53	Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2471-2482.	2.8	259
54	Atrial fibrillation and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2014, 29, 595-600.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 857-862.	2.2	18
56	Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 717-722.	3.9	63
57	Incidence and Influence of Hospitalization for Recurrent Syncope and Its Effect on Short- and Long-Term All-Cause and Cardiovascular Mortality. <i>American Journal of Cardiology</i> , 2014, 113, 1744-1750.	1.6	17
58	Antithrombotic Treatment in Patients With Heart Failure and Associated Atrial Fibrillation and Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2689-2698.	2.8	25
59	Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant. <i>Circulation</i> , 2014, 129, 1577-1585.	1.6	256
60	Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1270-1280.	2.8	53
61	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 231-232.	2.8	0
62	Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1281-1287.	1.9	0
63	Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 832-837.	1.7	13
64	Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope. <i>Journal of the American College of Cardiology</i> , 2013, 61, 325-332.	2.8	76
65	Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2013, 62, 981-989.	2.8	313
66	Comparison of Incidence, Predictors, and the Impact of Co-Morbidity and Polypharmacy on the Risk of Recurrent Syncope in Patients ≥ 85 Versus ≤ 85 Years of Age. <i>American Journal of Cardiology</i> , 2013, 112, 1610-1615.	1.6	43
67	Automated External Defibrillators Inaccessible to More Than Half of Nearby Cardiac Arrests in Public Locations During Evening, Nighttime, and Weekends. <i>Circulation</i> , 2013, 128, 2224-2231.	1.6	122
68	Accuracy of the ICD-10 discharge diagnosis for syncope. <i>Europace</i> , 2013, 15, 595-600.	1.7	64
69	Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. <i>Europace</i> , 2013, 15, 781-786.	1.7	66
70	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. <i>BMJ Open</i> , 2013, 3, e002758.	1.9	155
71	Response to Letter Regarding Article, "Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study". <i>Circulation</i> , 2013, 127, e585.	1.6	2
72	Evaluation of the CHADS ₂ Risk Score on Short- and Long-Term All-Cause and Cardiovascular Mortality After Syncope. <i>Clinical Cardiology</i> , 2013, 36, 262-268.	1.8	29

#	ARTICLE	IF	CITATIONS
73	Unexplained Syncope and Diagnostic Yield of Tests in Syncope According to the ICD-10 Discharge Diagnosis. <i>Journal of Clinical Medicine Research</i> , 2013, 5, 441-50.	1.2	9
74	Long-Term Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drug Use According to Time Passed After First-Time Myocardial Infarction. <i>Circulation</i> , 2012, 126, 1955-1963.	1.6	102
75	The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study. <i>Europace</i> , 2012, 14, 1506-1514.	1.7	88
76	Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention. <i>Circulation</i> , 2012, 126, 1185-1193.	1.6	381
77	Use of nonsteroidal anti-inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 428-434.	1.9	17
78	Response to Letters Regarding Article, "Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study". <i>Circulation</i> , 2011, 124, .	1.6	0
79	Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2226-2235.	1.6	291